Dr. Kennecke on Suggested Multidisciplinary Actions for GEP-NETs

Publication
Video
Supplements and Featured PublicationsTherapeutic Updates in Neuroendocrine Tumors
Volume 1
Issue 1

Hagen F. Kennecke, MD, MHA, FRCPC, discusses multidisciplinary interactions within Virginia Mason Medical Center for patients with gastroenteropancreatic neuroendocrine tumors.

Hagen F. Kennecke, MD, MHA, FRCPC, a medical oncologist at Virginia Mason Medical Center, discusses multidisciplinary interactions within Virginia Mason Medical Center for patients with gastroenteropancreatic neuroendocrine tumors.

At a weekly tumor board, Kennecke will present a patient’s history, provide their background, and sequentially review pathology. Pathology must be analyzed to ensure the tumor grade is assessed with Ki-67 differentiation. After, imaging is conducted and repeat imaging is ordered if multi-phase CT scans are not completed, says Kennecke.

Then, the Gallium-68 dotatate (Netspot) PET/CT scan is reviewed and a Krenning score is assigned to all patients, grading to tumors from 0 to 4, according to Kennecke. From this evaluation of the patient, the tumor board decides what the best strategy is before discussing with the patients, he concludes.

Related Videos
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"